Trials / Completed
CompletedNCT02568319
Safety and Efficacy Study of LIPO-202 for the Reduction of Central Abdominal Bulging in Obese Subjects
A Phase 2 Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Safety and Efficacy of LIPO-202 for the Reduction of Central Abdominal Bulging in a Defined Special Population - Obese Subjects (BMI > or Equal to 30 kg/m2)
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 120 (estimated)
- Sponsor
- Neothetics, Inc · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a multi-center, randomized, placebo-controlled, double-blind study evaluating the safety and efficacy of LIPO-202 for the reduction of central abdominal bulging in obese subjects.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | LIPO-202 | |
| DRUG | Placebo |
Timeline
- Start date
- 2015-09-01
- Primary completion
- 2015-12-01
- First posted
- 2015-10-05
- Last updated
- 2015-12-24
Locations
6 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT02568319. Inclusion in this directory is not an endorsement.